Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov

It is evident that traditional endocrine treatments play a pivotal role in the management of HR+ BC. However, the emergence of resistance necessitates the development of novel therapeutic strategies. These strategies should be based on pharmacokinetics, further investigation of the molecular signaling pathways of BC, such as new SERMs, SERDs, PROTACs, as well as new drug groups, like SERCAs, CERANs, SHERPAs. Combination therapy represents the most promising avenue for BC treatment. While PROTAC combination with new monotherapeutic agents for BC treatment has yet to be investigated, we believe that such combinations have the potential to make the treatment more selective, effective, and personalised in the future.

Authors

Institutions

Publication Details

Journal
Current Medicinal Chemistry
Published
2025-03-19
DOI
https://doi.org/10.2174/0109298673345472250301052255
Citations
3
Primary Topic
Advanced Breast Cancer Therapies
Type
article
Field-Weighted Citation Impact
4.56
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov

Vladimir N. Chubarev, Samsonov MIu, Маргарита Е. Неганова, Александр Владимирович Самородов et al.
3 citations
Current Medicinal Chemistry
Advanced Breast Cancer Therapies
4.56
article

Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov

Vladimir N. Chubarev, Samsonov MIu, Маргарита Е. Неганова, Александр Владимирович Самородов, K. A. Nazmieva, Olga Sukocheva, Polina Abdullaeva, Е. А. Smolyarchuk, Sabina Abdullaeva, Junqi Liu, Renata A. Gabdrakhimova
article en
3 citations

Abstract

It is evident that traditional endocrine treatments play a pivotal role in the management of HR+ BC. However, the emergence of resistance necessitates the development of novel therapeutic strategies. These strategies should be based on pharmacokinetics, further investigation of the molecular signaling pathways of BC, such as new SERMs, SERDs, PROTACs, as well as new drug groups, like SERCAs, CERANs, SHERPAs. Combination therapy represents the most promising avenue for BC treatment. While PROTAC combination with new monotherapeutic agents for BC treatment has yet to be investigated, we believe that such combinations have the potential to make the treatment more selective, effective, and personalised in the future.

Current Medicinal ChemistryVol. 32(36)
National University of Science and Technology (RU), Royal Adelaide Hospital (AU), Sechenov University (RU), A. N. Nesmeyanov Institute of Organoelement Compounds (RU), R-Pharm (Russia) (RU), Bashkir State Medical University (RU), First Affiliated Hospital of Zhengzhou University (CN)
Good health and well-being
Openalex Percentile: Top 6%
Advanced Breast Cancer Therapies
4.56
DOISourceOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.